



Aurobindo surges 13% on FDA nod

Shares of Aurobindo Pharma on Monday climbed nearly 13 per cent after the drug maker received the final approval from the US health regulator to manufacture and market its generic version of anti-depressant drug Cymbalta in the US market.

Scripts of the drug firm settled 12.62 per cent higher at Rs 348.95 on BSE. At NSE, the stock jumped 12.90 per cent to end the trade at Rs 350.

Company.